Overview
As foreign investment continues to increase across Singapore and Asia Pacific, it’s important for biotech startup founders to understand the network of investors entering the region and the types of innovations those investors are seeking.
JLABS Singapore, Johnson & Johnson, is hosting an event to Meet with MPM BioImpact, a US-based biotechnology investment firm that has been the key driver of many successful biotech exits, and has recently expanded into Asia. During this event, meet with their investment team as they discuss their focus areas and their outlook on growth in Asia Pacific. With over $3 billion under management across early-stage venture funds in biotechnology, take advantage of the opportunity to hear from this team of experts on how to build successful biotech companies.
Following the session, join us for networking with the MPM BioImpact team and the life science community.
Schedule
Date: 26 Jul 2024, Friday
Time: 4:00 PM - 7:00 PM (GMT +8:00) Kuala Lumpur, Singapore
Location: The Metro, 2 Science Park Drive, Ascent, Level 1, Singapore Science Park 1, Singapore, 118222
Speakers
Speaker's Profile:
Ansbert Gadicke, M.D., Managing Partner, MPM BioImpact
Dr. Ansbert Gadicke is the Managing Partner of MPM BioImpact. Ansbert founded MPM Capital in 1992 as a biotech venture capital firm and later its affiliate BioImpact Capital for private/public funds. He is the driving force at MPM BioImpact behind building leading biopharmaceutical companies such as BioMarin Pharmaceuticals, Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), and Pharmasset (acquired by Gilead Sciences) and, more recently, Cullinan Oncology (NASDAQ: CGEM), ElevateBio, Orna Therapeutics and ReNAgade Therapeutics (acquired by Orna). Ansbert received an M.D. from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University.
Speaker's Profile:
David Kolesky, Ph.D., Principal, MPM BioImpact
Dr. David Kolesky is responsible for driving investments and company creation activities. Before joining MPM BioImpact, David was a Principal at Flagship Pioneering, where he focused on conceiving, creating, and operating new bioplatform technology companies. David co-founded and helped launch several companies, notably Senda Biosciences and Montai Health, where he held key leadership roles at early stages of development including Chief Scientific Officer and Chief Innovation Officer at Montai, and Head of Platform at Senda. David has developed a wide range of scientific and technical experience by working across diverse platforms, including AI-enabled small molecule discovery, programmable delivery of genomic medicines, and cell & tissue engineering. David received his Ph.D. in Engineering Sciences from Harvard University and conducted a postdoctoral fellowship at the Wyss Institute for Biologically Inspired Engineering.
Moderator's Profile:
Alessandro Falcone, MD, MSc, Head, JLABS Singapore, Johnson & Johnson Innovation, Johnson & Johnson
As Head of JLABS Singapore, Alessandro is responsible for charting the strategic direction and overseeing all portfolio and business operational activities. Before assuming this role, Alessandro held the position of Executive Director in Oncology R&D at AstraZeneca, concentrating on the clinical development of the breast cancer portfolio. Prior to that, he occupied senior R&D and commercial positions at GSK and Novartis, respectively, over the past decade. At Novartis, he spearheaded European strategy and operations, while at GSK, he led technology and partnerships for all R&D endeavors. Alessandro's career also encompasses significant experience at top life science strategy consultancies such as LEK and IQVIA, with a particular focus on international investments in the life science sector.
